Coffee Intake of Colorectal Cancer Patients and Prognosis According to Histopathologic Lymphocytic Reaction and T-Cell Infiltrates.

Aged Coffee Colorectal Neoplasms / mortality Female Humans Male Middle Aged Proportional Hazards Models Retrospective Studies T-Lymphocytes / metabolism

Journal

Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543

Informations de publication

Date de publication:
01 2022
Historique:
received: 15 09 2020
revised: 19 08 2021
accepted: 10 09 2021
entrez: 8 1 2022
pubmed: 9 1 2022
medline: 10 2 2022
Statut: ppublish

Résumé

Given previous biologic evidence of immunomodulatory effects of coffee, we hypothesized that the association between coffee intake of colorectal cancer patients and survival differs by immune responses. Using a molecular pathologic epidemiology database of 4465 incident colorectal cancer cases, including 1262 cases with molecular data, in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined the association between coffee intake of colorectal cancer patients and survival in strata of levels of histopathologic lymphocytic reaction and T-cell infiltrates in tumor tissue. We did not observe a significant association of coffee intake with colorectal cancer-specific mortality (multivariable-adjusted hazard ratio [HR] for 1-cup increase of coffee intake per day, 0.93; 95% CI, 0.84 to 1.03). Although statistical significance was not reached at the stringent level (α=.005), the association of coffee intake with colorectal cancer-specific mortality differed by Crohn disease-like lymphoid reaction (P

Identifiants

DOI: 10.1016/j.mayocp.2021.09.007 PMID: 34996545 PMC: PMC8820462
pubmed: 34996545
pii: S0025-6196(21)00703-5
doi: 10.1016/j.mayocp.2021.09.007
pmc: PMC8820462
mid: NIHMS1763083
pii:
doi:

Substances chimiques

Coffee 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-133

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA118553
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248857
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA263776
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK098311
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169141
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA215314
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA253185
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA188126
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Références

Annu Rev Pathol. 2019 Jan 24;14:83-103
pubmed: 30125150
J Clin Oncol. 2015 Nov 1;33(31):3598-607
pubmed: 26282659
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
N Engl J Med. 2007 May 24;356(21):2131-42
pubmed: 17522398
PLoS One. 2013 Sep 20;8(9):e75139
pubmed: 24073240
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):
pubmed: 33408252
Br J Cancer. 2020 Apr;122(9):1367-1377
pubmed: 32157241
Clin Cancer Res. 2009 Oct 15;15(20):6412-20
pubmed: 19825961
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Gut. 2018 Jun;67(6):1168-1180
pubmed: 29437869
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Eur J Cancer. 2018 Nov;103:98-107
pubmed: 30219720
Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36
pubmed: 1632423
Pharmacol Ther. 2006 Sep;111(3):877-92
pubmed: 16540173
Clin Cancer Res. 2021 May 15;27(10):2816-2826
pubmed: 33632927
Eur J Epidemiol. 2018 Apr;33(4):381-392
pubmed: 29264788
Gastroenterology. 2018 Mar;154(4):916-926.e9
pubmed: 29158191
Gut. 2017 Oct;66(10):1790-1796
pubmed: 27436272
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Nat Immunol. 2017 Jul 19;18(8):843-850
pubmed: 28722707
EBioMedicine. 2020 Jul;57:102860
pubmed: 32652320
Trends Immunol. 2019 Apr;40(4):292-309
pubmed: 30871979
JNCI Cancer Spectr. 2018 Oct;2(4):pky058
pubmed: 31276098
Autoimmun Rev. 2017 Jul;16(7):712-721
pubmed: 28479483
PLoS One. 2008;3(11):e3698
pubmed: 19002263

Auteurs

Tomotaka Ugai (T)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA. Electronic address: tugai@bwh.harvard.edu.

Koichiro Haruki (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Juha P Väyrynen (JP)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.

Jennifer Borowsky (J)

Conjoint Gastroenterology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.

Kenji Fujiyoshi (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Mai Chan Lau (MC)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Naohiko Akimoto (N)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Rong Zhong (R)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.

Junko Kishikawa (J)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Kota Arima (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Shan-Shan Shi (SS)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Melissa Zhao (M)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Charles S Fuchs (CS)

Yale Cancer Center, New Haven, CT; Department of Medicine, Yale School of Medicine, New Haven, CT; Smilow Cancer Hospital, New Haven, CT.

Xuehong Zhang (X)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.

Marios Giannakis (M)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA.

Mingyang Song (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston; Division of Gastroenterology, Massachusetts General Hospital, Boston.

Hongmei Nan (H)

Department of Global Health, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis; Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis.

Jeffrey A Meyerhardt (JA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Molin Wang (M)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.

Jonathan A Nowak (JA)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Shuji Ogino (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA. Electronic address: sogino@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Aliments et boissons › Boissons › Café › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Coffee Intake of Colorectal Cancer Patients...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Coffee Intake of Colorectal Cancer Patients...